ライフサイエンスコーパス: partial response

1 the combined rates of complete response and partial response).

2 response, 7% very good partial response, 58% partial response).

3 or responses (two complete responses and one partial response).

4 ort that received 8 mg per kilogram (3 had a partial response).

5 ed, six had a null response, and three had a partial response).

6 e response (two complete responses and three partial responses).

7 was 38% (including eight complete and seven partial responses).

8 erall response (two complete responses, nine partial responses).

9 tive responses (four complete responses; two partial responses).

10 to 32.7%; five complete responses and three partial responses).

11 A relapse was defined as loss of partial response.

12 achieving a complete response and 21 (58%) a partial response.

13 CR and 6 months in those who had obtained a partial response.

14 eported confirmed or unconfirmed complete or partial response.

15 tients had a complete response, and 10 had a partial response.

16 a complete response, and 3 (27%) achieved a partial response.

17 one patient (6%; 95% CI 0.0-16.1) achieved a partial response.

18 Best response was partial response.

19 complete response, and 22 (44%, 30.0-58.7) a partial response.

20 and 3 infusions of kappa.CARTs, and 1 had a partial response.

21 d a complete response and 7 (28%) achieved a partial response.

22 itive/HER2-negative cancers, 33 patients had partial response.

23 econd course 1 month later for patients with partial response.

24 were not observed; 12 patients experienced a partial response.

25 nown to be responsive to irinotecan achieved partial response.

26 had a complete response and six (22%) had a partial response.

27 7_G778insGSP mutation and achieved a durable partial response.

28 gically, and only 2-3% of patients achieve a partial response.

29 l response rate (ORR) defined as complete or partial response.

30 (11% [2-29]) complete and four (15% [4-34]) partial responses.

31 s, including eight complete responses and 20 partial responses.

32 PD-L1; however, PD-L1 inhibition only led to partial responses.

33 gastro-oesophageal adenocarcinoma; all were partial responses.

34 esponses and 10 months (range, 7 to 10+) for partial responses.

35 onse, including one complete response and 21 partial responses.

36 ponse rate of 28% (9 patients), and all were partial responses.

37 There were two complete responses and seven partial responses.

38 ng nine (6%) complete responses and 18 (11%) partial responses.

39 11 (61%) achieved an objective (complete or partial) response.

40 (odds ratio, 0.16; P = 0.03), previous null/partial response (0.24; P = 0.02), IL28B genotype CC (7.

41 as minimal response or better), including 5 partial responses (1 patient on schedule A and 4 on sche

42 /kg, 14 [38%] with 20 mg/kg); and 20 (27%) a partial response (10 [28%] with 10 mg/kg, 10 [27%] with

43 was 87.1% (1 complete response, 10 very good partial responses, 10 partial responses, and 6 minimal r

44 all response (153 complete responses and 149 partial responses); 11 (37.9%; 20.7-57.7) of 29 patients

45 ith thymoma, one (6%, 95% CI 0.2-30.2) had a partial response, 12 (75%, 47.6-92.7) had stable disease

46 Of the 25 patients, 10 (40%) had a partial response, 13 (52%) had stable disease, and two (

47 1 evaluable patients, one (5%) patient had a partial response, 14 (67%) patients had stable disease,

48 ab there were 14 complete responses and nine partial responses; 14 patients had stable disease, and n

49 f 120), including 13 complete (10.8%) and 18 partial responses (15%).

50 Thirteen patients (28.9%) had a partial response, 15 patients (33.3%) experienced diseas

51 26%, 90% CI 12.1-45.3, 95% CI 10.2-48.4) had partial responses, 15 (65%, 95% CI 42.7-83.6) achieved s

52 ), very good partial response (9 [19%]), and partial response (16 [33%]); median duration of response

53 By day 42, four patients (11%) had a partial response, 16 (43%) had stable invasive fungal di

54 8 [76%] with 20 mg/kg); 31 (42%) a very good partial response (17 [47%] with 10 mg/kg, 14 [38%] with

55 plete responses (CRs; 14.7%) and 8 very-good-partial responses (23.5%).

56 , 3 complete responses (9%), and 9 very good partial responses (28%).

57 onse, 12%; complete response, 10%; very good partial response, 28%; and partial response, 36%) and 10

58 (18%) had a complete response, 9 (53%) had a partial response, 3 (18%) had stable disease, and 2 (12%

59 ments, ORR was 100% (complete response, 67%; partial response, 33%).

60 umors (grade 3 or 4) (complete response, 0%; partial response, 33%; SD or DP, 67%) (P < .001).

61 e, 10%; very good partial response, 28%; and partial response, 36%) and 100% among high-risk patients

62 in 87% of patients (complete response, 49%; partial response, 38%; stable disease [SD] or local dise

63 ponse rate was 31.1%, including 13 very good partial responses, 4 complete responses, and 3 stringent

64 atients treated, one patient had a confirmed partial response (5%; 95% CI, 1% to 24%) and seven other

65 ical response (complete response, 78% v 76%; partial response, 5% v 9%) and failures (no response, 15

66 esponded (3% complete response, 7% very good partial response, 58% partial response).

67 patients), 100% among patients with a prior partial response (65 of 65 patients), and 95.2% among pa

68 se rate was 21% (complete response = 4 [8%]; partial response = 7 [13%]) and 10 (19%) patients had st

69 A patient with metastatic RCC experienced a partial response (78% shrinkage, progression-free surviv

70 red eleven of 126 patients had a complete or partial response (88%; 95% CI, 81% to 93%), of whom 88 h

71 sponse/complete response (4 [8%]), very good partial response (9 [19%]), and partial response (16 [33

72 ts with radiologically confirmed complete or partial response according to Response Evaluation Criter

73 Patients with less than partial response after 3 cycles received oral dexamethas

74 lymphocytic leukaemia who are in complete or partial response after at least two lines of treatment;

75 nts who did not achieve complete response or partial response after chemotherapy with or without seco

76 SCLC patients that had clinically achieved a partial response after dacomitinib treatment.

77 isk for an early progression with at least a partial response after four or more cycles of first-line

78 d with two lines of therapy (with at least a partial response after second-line therapy); had receive

79 roup analyses, participants who demonstrated partial response also experienced clinically meaningful

80 response rate was 95%, including 85% with a partial response and 10% with a partial response with ly

81 One vs 5 patients had a partial response and 12 vs 14 patients had stable diseas

82 omplete response (non-CMR): 15 patients with partial response and 17 with disease progression.

83 ts with tenosynovial giant-cell tumors had a partial response and 7 patients had stable disease.

84 n cohort (n = 34), five patients (15%) had a partial response and eight patients (24%) had stable dis

85 One patient achieved a partial response and experienced significant improvement

86 response; five (29%) experienced a confirmed partial response and have been on study for more than 2

87 We conclude that survival with a complete or partial response and no previous secondary systemic trea

88 filtrations showed that seven patients had a partial response and one patient had stable disease acco

89 t a threshold of 30% change in SUV to define partial response and progressive disease.

90 The observed clinical activity (partial response and prolonged progression-free survival

91 an objective response: six (40%) achieved a partial response and six (40%) a partial response with l

92 the 34 patients restaged, one patient had a partial response and ten had stable disease.

93 6.7) had objective responses, including four partial responses and five complete responses.

94 h a complete response and 2 with a very good partial response) and 10% in the cohort that received 8

95 nvatinib group (4 complete responses and 165 partial responses) and 1.5% in the placebo group (P<0.00

96 One patient had a partial response, and 10 patients had stable disease.

97 patients evaluable for response, two showed partial response, and 13 exhibited stable disease.

98 3 patients had a complete response, 6 had a partial response, and 3 had stable disease at last follo

99 (23%) had a complete response, 2 (9%) had a partial response, and 6 (27%) had decreased tumor burden

100 h multiple nonbiopsied tumors, four achieved partial response, and four had stable disease.

101 rimary endpoint (complete clinical response, partial response, and no response) and secondary endpoin

102 ive patients improved from stable disease to partial response, and one patient improved from partial

103 Complete response, partial response, and stable disease as best response we

104 ad a complete response, five of 20 who had a partial response, and three of five who had a minor resp

105 %); four patients (17%) achieved a confirmed partial response, and three patients (13%) had stable di

106 response, 10 very good partial responses, 10 partial responses, and 6 minimal responses) and was not

107 rate was 26%, including one complete and 11 partial responses, and the median PFS was 4.8 months.

108 med objective response (complete response or partial response) assessed according to RECIST version 1

109 lete responses at 120 mg once a day, and one partial response at 80 mg once a day), and six additiona

110 , three patients with liposarcoma achieved a partial response (at 250, 400, and 500 mg), 31 showed st

111 t was tumor response (complete response plus partial response) at 3 mo.

112 response, unconfirmed complete response, and partial response) at the end of induction.

113 e of autopleurodesis, defined as complete or partial response based on symptomatic and radiographic c

114 Two patients had confirmed partial responses; both had gpNMB-positive tumors and on

115 om baseline to a final value </=133 mumol/L, partial response by a decrease >/=50% of sCr from baseli

116 l benefit rate (stable > 6 months [n = 7] or partial response by RECIST criteria [n = 3]) was 26.3% (

117 patients achieving an objective (complete or partial) response by central review after six cycles of

118 Three women achieved a partial response (CNS objective response rate, 8%; 95% C

119 Complete and partial responses combined were between 26.7% and 65%.

120 hieved a hematologic response (14% very good partial response/complete response [VGPR/CR]), with medi

121 verage objective response rate (complete and partial responses, CR and PR, respectively) was 50% (95%

122 aracteristics analysis identified a low-dFLC partial response (dFLC <10 mg/L for patients with a dFLC

123 ients with SMM achieved at least a very good partial response during the study period.

124 e (final cutaneous ePOST score of 0 or 1) or partial response (ePOST drop >/=2 points from baseline b

125 ort, none of 12 patients (95% CI 0-26) had a partial response, five had stable disease, and seven had

126 Patients with a complete or partial response following induction therapy continued i

127 o relapsed was retreated and has remained in partial response for more than 23 months.

128 patients (9 adults and 7 children), 1 had a partial response for more than 9 months, 7 had stable di

129 Five (20%) patients had a partial response, for an objective response of 20% (95%

130 ts (73%) achieved CR, and six (10%) achieved partial response, for an overall response rate of 83%.

131 Two partial responses (>/= 18 months, >/= 7 months) and seve

132 Six partial responses (>/= 5 to >/= 8 months) and three stab

133 Two partial responses (>/=15 months and >/= 11 months) and e

134 two of three evaluable patients achieving a partial response had PIK3CA mutations.

135 Unraveling mechanisms underlying partial responses has implications in the design of ther

136 lete response unconfirmed in three (8%), and partial response in 12 (32.4%) for an overall response r

137 d complete response in one (2%), a confirmed partial response in 14 (32%), and an unconfirmed partial

138 ts achieved an objective response, including partial response in 18 patients (55%) and partial respon

139 b was 76%, including CR in 36% and very good partial response in 24%.

140 90%, comprising complete response in 47% and partial response in 43% of patients; the best individual

141 s a complete response in 21% of patients and partial response in 47%.

142 , resulting in complete response in 9 (53%), partial response in 5 (29%), and no response in 3 (18%).

143 mission was observed in one patient with TC, partial response in five patients (T, n = 3; TC, n = 2),

144 ial response in 14 (32%), and an unconfirmed partial response in nine (20%).

145 The rate of complete or partial response in the combination group was 68%, as co

146 .5%), major response in three (23.1%), and a partial response in three (23.1%) patients, whereas two

147 onses occurred in 65 (63%, 95% CI 53-72) and partial responses in 28 patients (27%, 19-37).

148 actory DLBCL, ibrutinib produced complete or partial responses in 37% (14/38) of those with ABC DLBCL

149 esponses were noted in 15 (52%) patients and partial responses in four (14%).

150 (95% CI, 29.6% to 56.7%), respectively, with partial responses in seven (13.0%) and eight (14.5%) pat

151 portion of patients who achieved complete or partial response) in all patients and by PD-L1 expressio

152 est overall response of complete response or partial response) in patients with measurable disease at

153 se rate was 77% (15 complete responses and 8 partial responses) in 30 evaluable patients.

154 This partial response is consistent with redundancy in chemok

155 ble disease (k=0.90, percent agreement=95%), partial response (k=0.96, percent agreement=98.1%) and c

156 erall survival (OS) compared with near-CR or partial response (median PFS, 27, 27, and 29 months, res

157 was 32% (11 of 35 patients; nine CRs and two partial responses; median, 15 cycles; range, eight to 29

158 sponse will be defined as complete response, partial response, minor response, stable disease, or pro

159 nses were complete response (n = 2 [2%]) and partial response (n = 30 [34%]).

160 Best responses included partial response (n = 4) and stable disease (n = 57).

161 e confirmed objective response rate was 30% (partial response, n = 19; complete response, n = 2), the

162 responses to TAE (complete response, n = 6; partial response, n = 5) and 11 patients were nonrespond

163 e increased the ORR with all responses of >/=partial response occurring in the 45 mg/m(2) selinexor p

164 ates were similar, with at least a very good partial response of 47% and 45%, respectively.

165 Computed tomography revealed partial response of hepatic metastases in 7 patients (25

166 nse (three unconfirmed) and five (24%) had a partial response (one unconfirmed); eight (38%) patients

167 cine courses; 19 had stable disease, two had partial responses, one had a minor response, and two had

168 Two patients (4.4%) had a partial response; one had squamous cell carcinoma (SCC)

169 was 21% (14/66), and 15% achieved very good partial response or better (>/=VGPR).

170 ORR) was 67% (44/66); 42% achieved very good partial response or better (>/=VGPR).

171 2%, P<0.001), as were the rates of very good partial response or better (59.2% vs. 29.1%, P<0.001) an

172 55 response-evaluable patients, 15% achieved partial response or better (76% stable disease or better

173 5% and 63%, respectively; rates of very good partial response or better after induction and consolida

174 dies are generally well tolerated and induce partial response or better in approximately 30% of heavi

175 Very good partial response or better occurred in 36% of patients (

176 oad T-cell changes, although patients with a partial response or better showed greater maximum effect

177 The rate of partial response or better was 64%; median duration of r

178 placebo group, and median time to response (partial response or better) was 1.51 months (1.41-1.64)

179 Median duration of response (partial response or better) was 13.14 months (95% CI 11.

180 The rates of overall response (partial response or better) were 82% (176/216) in the VR

181 The rates of overall response (partial response or better) were 87.1% and 66.7% in the

182 ceived 16 mg per kilogram (15 patients had a partial response or better, including 2 with a complete

183 Of 43 patients, five (12%) achieved a partial response or better, including one (2%) complete

184 ysis among patients who attained a very good partial response or better, the monotypic PCs at the 0.1

185 31-55) of the patients achieved a confirmed partial response or better, with 31% achieving a respons

186 overall survival compared with patients with partial response or better.

187 e was observed in 68% of patients (very good partial response or complete response in 29%), as well a

188 with an overall response that was equal to a partial response or greater within 16 cycles of treatmen

189 t of an overall response that was equal to a partial response or greater.

190 pies help many patients, but high rates of a partial response or no response, and the delayed onset o

191 whom had platinum-refractory disease, had a partial response or prolonged stable disease (10, >/= 6,

192 mplete response, very good partial response, partial response, or minor response) compared with only

193 benefit rate (CBR), which was defined as CR, partial response, or stable disease (>/= 16 weeks) by RE

194 the target lesions showed complete response, partial response, or stable disease (disease control) at

195 ment at month 9 showing a complete response, partial response, or stable disease according to local R

196 rall lesion assessment of complete response, partial response, or stable disease was 16 of 41 patient

197 n of proven or suspected lesion due to ECD), partial response (partial resolution of proven or suspec

198 e resolution of symptoms attributed to ECD), partial response (partial resolution of symptoms attribu

199 therapy (either complete response, very good partial response, partial response, or minor response) c

200 ho achieved a confirmed complete response or partial response per Response Evaluation Criteria In Sol

201 The spectral data were analyzed using partial response plots, and identified non-linearity mod

202 linical benefit rate (complete response plus partial response plus stable disease >/= 24 weeks) and p

203 trol rate (defined as complete response plus partial response plus stable disease) was 94% according

204 an overall response (complete responses plus partial responses plus minor responses) after each treat

205 Response rates by RECIST: partial response (PR) 21% (17/82), stable disease (SD) 4

206 ase in lymphadenopathy, resulting in 1 IWCLL partial response (PR) and 3 PRs with lymphocytosis.

207 tly higher in patients who achieved at least partial response (PR) compared with patients who achieve

208 Best response was partial response (PR) in four patients [(overall respons

209 Patients at IR with a partial response (PR) received three cycles of PE plus t

210 BCL who achieved a complete response (CR) or partial response (PR) to R-CHOP induction.

211 lded two continuous complete remissions, one partial response (PR) using RECIST criteria (two PRs usi

212 A partial response (PR) was a secondary end point, defined

213 tic value of different parameters defining a partial response (PR) was further investigated.

214 s at our institution who achieved at least a partial response (PR) with various therapies between 199

215 He again experienced initial partial response (PR), but by 18 months, he had experien

216 achieved complete response (CR) and 14 (31%) partial response (PR).

217 primary endpoint was overall response rate (partial response [PR] + very good PR + complete response

218 r response (TriTR; complete response [CR] or partial response [PR] v stable disease [SD] v progressiv

219 response rate (complete response [CR] and/or partial response [PR]) by International Workshop on Chro

220 in the VTD arm achieved at least a very good partial response (primary end point) vs 56.2% in the VCD

221 Those with a complete or partial response proceeded with consolidation HDC with t

222 her B-cell lymphomas also responded: 1 CR, 2 partial responses (PRs) of 6 with gray zone, 1 CR of 6 w

223 The overall confirmed partial response rate (PR) was 3 of 27 (11%), including

224 Similar to imatinib, the partial response rate for regorafenib by Choi (29%) was

225 e infusion produced a cumulative complete or partial response rate of 92% (95% CI, 78.1% to 98.3%) ov

226 Very good partial response rate or better at the completion of ind

227 The partial response rate was 16% (four of 25 patients; 95%

228 oint of the phase II trial was complete plus partial response rate.

229 e 3 or greater (NDMM) and at least very good partial response rates (SMM).

230 Partial response rates were 0% (none of six), 10% (two o

231 54 Gy radiation, and 20 (45%) with less than partial responses received 60 Gy.

232 udy met its primary endpoint, with confirmed partial responses seen in seven of 25 response-assessabl

233 onse after the redosing cycle; 15 (41%) with partial responses, seven (19%) with minor responses.

234 Antitumor activity (seven partial responses [six confirmed]) was demonstrated with

235 Ten patients (33.3%) achieved partial response, six (20%) had stable disease, and seve

236 d clinical benefit rate (complete response + partial response + stable disease >/= 4 months), 43%.

237 e clinical benefit rate (complete response + partial response + stable disease >/= 6 months) was 46%.

238 Complete and partial response, stable disease, and progressive diseas

239 ty was lower among patients with complete or partial response than among those with stable or progres

240 ete response and 6 months among those with a partial response; the median treatment-free survival was

241 17% with a complete response and 70% with a partial response; the remaining 3 patients (13%) had sta

242 l, five of 23 patients (21.7%) met PFS3 (two partial response, three stable disease).

243 cal efficacy was noted in five patients (two partial response, three stable disease).

244 asurable disease at baseline had a confirmed partial response; thus, the proportion of patients achie

245 tem with autoimmune pathogenesis, have shown partial response to a number of immunomodulating treatme

246 n index patient with NOTCH1-mutant ACC had a partial response to brontictuzumab.

247 of identified CAPS patients who show only a partial response to IL-1 blockade.

248 ited-stage disease who achieve a complete or partial response to initial therapy and may do so in sim

249 Interestingly, complete response but not partial response to MSCs was associated with overall sur

250 Partial response to proton pump inhibitor (PPI) therapy

251 itive ovarian cancer following a complete or partial response to second-line or later platinum-based

252 f the mutated MET allele experienced a major partial response to the c-Met inhibitor crizotinib.

253 motherapy regimens, had achieved complete or partial response to their last platinum-based regimen, h

254 However, most patients did show a partial response to vaccination.

255 There were 7 complete responses and 8 partial responses to combination carmustine and O6-benzy

256 rapeutic implications for CAPS patients with partial responses to IL-1-targeted therapies.

257 24 (55%) patients with complete or partial responses to induction chemotherapy received 54

258 An objective (complete or partial) response to treatment was associated with a hig

259 -determined overall response-ie, complete or partial response (treatment success) or stable or progre

260 tment with selumetinib resulted in confirmed partial responses (tumor volume decreases from baseline

261 mong the responders, six patients achieved a partial response, two of which are ongoing and have not

262 ssociated with inferior PFS, whereas DHL and partial response ( v complete response) at transplant we

263 with risk, patients relapsing from very good partial response (VGPR) or better had a longer time to d

264 The rate of better than very good partial response (VGPR) was higher in more recent period

265 s 62%, with 43% achieving at least very good partial response (VGPR).

266 f salvage chemotherapy (complete response vs partial response vs stable disease) and primary refracto

267 than with doxorubicin (25% [20 patients, all partial response] vs 0%).

268 One partial response was 3 months in duration.

269 esponse for the four patients who achieved a partial response was 5.4 months (4.1 to 7.5 months).

270 ation of response for patients with at least partial response was 64.5 months.

271 te response was defined as zero lesions, and partial response was defined as a 50% or greater reducti

272 ormalisation of all affected lineages, and a partial response was defined in neutropenic patients as

273 w-up, a best overall response of complete or partial response was recorded in 27 patients (17%; 95% C

274 Overall response rate (complete and partial response) was 5.5%.

275 se to treatment, including both complete and partial response, was not significantly different betwee

276 ng rates of complete response plus very good partial response were 48% and 39%.

277 four confirmed responses and one unconfirmed partial response were observed in patients with glioblas

278 Patients achieving at least a partial response were randomly assigned to receive maint

279 onses were achieved in six (3%) patients and partial responses were achieved in 134 (67%) patients.

280 evaluable for response, one complete and six partial responses were observed (n = 7, 4%), with 27 pat

281 treated at the highest dose level, objective partial responses were observed in a patient with esopha

282 Partial responses were observed in one patient with uvea

283 Partial responses were observed in seven of nine patient

284 Confirmed partial responses were observed in two patients carrying

285 Partial responses were observed, but the duration of tre

286 Partial responses were recorded in ten of 26 patients in

287 onses, including 4 complete responses and 18 partial responses, which were observed across a spectrum

288 govitecan treatment; one patient achieved a partial response with a sustained response spanning > 2

289 ng partial response in 18 patients (55%) and partial response with lymphocytosis in 14 (42%).

290 Including 1 patient with partial response with lymphocytosis, the best ORR was 96

291 g 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of

292 achieved a partial response and six (40%) a partial response with lymphocytosis; the remaining three

293 nt of patients achieved complete response or partial response with neoadjuvant chemotherapy.

294 Success was defined as complete or partial response with no secondary systemic treatment or

295 ients achieved a CR and seven (13%) achieved partial responses with negative markers (PR-negative) fo

296 -experienced with prior relapse or a null or partial response) with chronic HCV GT1b infection receiv

297 1 of 17] complete response and 46% [8 of 17] partial response), with 18% (3 of 17) stable disease and

298 logical response rate was 54% (8 of 15) (all partial response), with 26% (4 of 15) stable disease and

299 an initial complete response and 10 (12%) a partial response, with a median response duration of 57

300 hirteen (33%) additional patients achieved a partial response, with a reduction in the PSA level to l